Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ACP-196 in Hepatic Insufficiency
NCT04867941Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Oct 2014
- Primary completion
- Feb 2015
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by Acerta Pharma. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity and Maximum Observed Plasma Concentration. Started Oct 2014; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04867941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867941.